Atrial Fibrillation Monitoring on Patients With Lymphoma After Chemotherapy

• Conditions: Atrial Fibrillation

• Registration Number: NCT05454878
• Lead Sponsor: Chinese PLA General Hospital

Brief Summary

This prospective cohort study is to investigate the incidence of atrial fibrillation after chemotherapy by aplying wearable ECG recoder and the risk factors on patients with newly diagonsed lymphoma

Detailed Description

This prospective, single-centre, observational cohort study is disigned to enroll 100 newly diagnosed lymphoma patients who met the inclusion and exclusion criteria to monitor the onset of atrial fibrillation and other arrhythmias during chemotherapy by using wearable ECG recorder, and to evaluate the incidence of atrial fibrillation and related risk factors.

Study Timeline

• Status Verified: 2022-06
• Study First Submitted: 2022-07-07
• Study First Submitted QC: 2022-07-07
• Last Update Submitted: 2022-07-07
• Study First Posted: 2022-07-12
• Last Update Posted: 2022-07-12
• Study Start: 2022-07-15
• Primary Completion: 2023-07-01
• Study Completion: 2023-12-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. At least 18 years old;
2. Concurrent chemotherapy on patients with new-onset lymphoma: chemotherapy regimens containing anthracyclines;
3. The subject voluntarily signed the informed consent.

Exclusion Criteria

1. With heart failure, acute stroke or acute coronary syndrome within 3 months before admission
2. With Atrial fibrillation on admission
3. Patient after pacemaker surgery
4. With mental illness or mentally disabled
5. Patients that the investigator considers as unsuitable for this test

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence	1 year after the first course of chemotherapy	Incidence of atrial fibrillation after chemotherapy

Trial Locations

Locations (1)

General hospital of PLA; 🇨🇳 Beijing, Beijing, China